- Liz Highleyman | 04 October 2013
Hepatocellular carcinoma is
frequently diagnosed at an advanced stage in HIV-positive people with hepatitis
B or C co-infection, contributing to a high mortality rate that has changed
little in recent years, according to ...
- Liz Highleyman | 04 October 2013
The investigational HIV integrase inhibitor GSK1265744 was
well tolerated, with no notable safety concerns, in a meta-analysis of eight
studies testing the drug as either a pill or a long-acting injection,
researchers reported ...
- Liz Highleyman | 04 October 2013
The incidence of acute hepatitis C virus (HCV)
co-infection has increased in recent years at the largest HIV clinic in Japan,
with almost all cases occurring among men who have sex with ...
- Liz Highleyman | 02 October 2013
The Stribild single-tablet regimen matched
both Atripla and boosted atazanavir (Reyataz) in efficacy amongst people age
50 and older, who responded as well as younger patients, researchers reported at the recent
53rd Interscience ...
- Liz Highleyman | 30 September 2013
An intravaginal ring containing tenofovir protected
all but one macaque monkey given hormonal contraceptives and repeatedly exposed
to a hybrid human/simian virus similar to HIV, according to a late-breaker
presentation at the 53rd
Interscience ...
- Liz Highleyman | 27 September 2013
People co-infected with HIV and HCV, mostly with hepatitis C
virus (HCV) genotype 3, responded about as well as HIV-negative people to interferon-based
therapy after taking into account other factors associated ...
- Liz Highleyman | 26 September 2013
Antiretroviral treatment that requires only a single
tablet taken once daily were associated with better viral suppression, higher adherence and lower likelihood of hospitalisation, researchers
reported at the 53rd
Interscience Conference on Antimicrobial ...
- Liz Highleyman | 25 September 2013
About two-thirds of
gay men and one-fifth of women tested in Spain were found to have cell or
tissue abnormalities that could progress to anal cancer, and both groups could
benefit from more ...
- Liz Highleyman | 23 September 2013
People who switched single-tablet regimens from Atripla
(efavirenz/tenofovir/emtricitabine) to Eviplera
(rilpivirine/tenofovir/emtricitabine) maintained viral suppression and saw
improvement in central nervous system (CNS) side-effects such as abnormal
dreams and depression, according to a late-breaking poster ...
- Liz Highleyman | 19 September 2013
Effective interferon-based therapy
that produces sustained virological response led to significant reductions in
liver decompensation, HIV disease progression and both overall and
liver-related mortality among people with HIV and hepatitis C co-infection, according ...
- Liz Highleyman | 18 September 2013
Antiretroviral regimens containing the integrase
inhibitor raltegravir (Isentress)
were shown to be safe and effective for pregnant women living with HIV and did not
cause birth defects in their infants, researchers reported last ...
- Liz Highleyman | 18 September 2013
People who experience episodes of major depressive
disorder (MDD) are significantly more likely to have episodes of detectable HIV in their cerebrospinal
fluid (CSF), according to an analysis of the large CHARTER ...
- Liz Highleyman | 17 September 2013
The next-generation HIV non-nucleoside reverse transcriptase inhibitor
(NNRTI) AIC292 showed good antiviral
activity, a high barrier to resistance and a favourable safety profile in laboratory
and animal studies presented at the 53rd Interscience ...
- Liz Highleyman | 17 September 2013
Blood levels of MK-1439, a next-generation HIV non-nucleoside reverse
transcriptase inhibitor (NNRTI) in phase 2b trials, rose significantly when
combined with ritonavir, but tenofovir had little effect, researchers reported
at the 53rd Interscience ...
- Liz Highleyman | 17 September 2013
The new integrase inhibitor dolutegravir worked better than boosted
darunavir for people starting HIV treatment for the first time, researchers reported last Thursday
at the 53rd Interscience Conference
on Antimicrobial Agents and Chemotherapy ...
- Gus Cairns | 13 September 2013
A
US survey of the prescribing of Truvada (tenofovir/emtricitabine)
to HIV-negative people as pre-exposure prophylaxis (PrEP) has found that, when
participants in clinical trials and demonstration projects are excluded, PrEP
recipients are more likely ...
- Liz Highleyman | 13 September 2013
Tenofovir alafenamide (TAF), a new
formulation that produces higher drug levels in cells but allows for lower
dosing, was as effective as the current tenofovir disoproxil fumarate (TDF)
formulation, but had less impact ...
- Liz Highleyman | 13 September 2013
The integrase inhibitor
raltegravir (Isentress) may be an
optimal choice for many HIV-positive people receiving cancer chemotherapy, as
it is highly effective and well-tolerated in this population, according to a
poster presentation at the ...
- Liz Highleyman | 13 September 2013
Two
people whose CD4 T-cells were modified to make them resistant to HIV entry experienced
substantial CD4 cell gains and were able to maintain viral suppression after
interruption of antiretroviral therapy (ART), according ...